Welcome
to Nordic Pharma

Making a sustainable impact on people’s health

Accueil

About The Group

Nordic Pharma is an international marketing and sales company with a history of internal product development and acquisitions.

Through a combination of innovation, collaboration and quality, Nordic Pharma strives to address specific unmet medical needs.

Nordic Pharma holds an established position in Women’s Health, a fast-growing Rheumatology franchise with global footprints and an increasing presence in Critical Care and Ophthalmology.We bring over 25 years of expertise since our creation in 1995.

News

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY AMRING PHARMACEUTICALS INC., ANNOUNCES JAI G. PAREKH, MD, MBA AS CHIEF COMMERCIAL OFFICER, EYE CARE U.S.
- by admin

BERWYN, PA — Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announces Jai G. Parekh, MD,…

Company news
BERWYN, PA -- Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S.

Nordic Pharma recently expanded its pharmaceutical expertise in the U.S. by acquiring
Visant Medical, Inc. (Visant), a leader in medical technology innovation in Dry Eye Disease (DED). This included the FDA-cleared hyaluronic acid derivative LACRIFILL®, a canalicular occlusive device, which is intended to temporarily block tear drainage by the occlusion of the canalicular system.

“With this exciting acquisition and our global plans for LACRIFILL, Dr. Parekh’s 25 years of eye care experience, strategic leadership, and deep understanding of eye care and the industry, make him the perfect choice to guide our commercial entry into the U.S. market,” said
Charlotte Phelps, CEO, Nordic Pharma. “As a practicing ophthalmologist, Dr. Parekh’s patient-driven focuswill also be invaluable for making a sustainable impact on the health of people with dry eye disease.”

Philip Gioia, President of the U.S. team that will launch LACRIFILL under the Nordic Pharma
brand said “I look forward to partnering with Jai in his new role. I’ve had the great opportunity to work with him while at other leading global Ophthalmology companies. He brings a world class, innovative, fresh perspective to eye care and his background, experience anarmamentariad reputation in our industry is second to none. In addition, having Andy Corley of Yelroc Consulting as a commercial advisor to Nordic Pharma following the Visant Medical acquisition, clearly sets us up for excellence as we prepare to launch LACRIFLL later this year.”

“I am honored to be a part of Nordic Pharma, a company known for its commitment to innovation and improving patient outcomes,” said Dr. Parekh. “I look forward to contributing to the growth and success of the organization by helping lead impactful commercial strategies. There are many ways to take care of dry eye patients and with this huge market opportunity, we believe LACRIFILL will be a significant part of the armamentaria.”
 
In addition to Dr. Parekh’s appointment, Nordic Pharma has formed its U.S. Medical Advisory Board which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma). Dr. Parekh continued, “I’m excited to have many of the top eye care leaders on our Medical Advisory Board. Together, we will help serve the unmet needs of so many ophthalmic patients in a state-of-the-art fashion.”
To start their new roles, Dr. Parekh and Andy Corley are representing Nordic Pharma at the Hawaiian Eye and Retina 2024 meeting this week. During the meeting they will be sharing LACRIFILL’s benefits with physicians and leaders in ophthalmology while also providing select pre-order opportunities.   About Jai G. Parekh, MD, MBA Dr. Parekh has been a long contributing member of the industry, most notably as former Chief Medical Officer at Allergan Eye Care. He sits on many advisory boards, societies and foundations including non-profits and serves as a serial advisor to many eye care organizations. Dr.Parekh is currently CEO/Co-Founder of Eyecare Consultants of NJ, a practicing ophthalmologist, and most recently hired by Inizio Engage as Chief Commercial Officer. He earned his MD at the early-acceptance medical program at the Boston University School of Medicine. A dual-trained internist and board-certified ophthalmologist, he completed his ophthalmology training/chief year at Boston University Medical Center and then went on to the New York Eye & Ear Infirmary where he completed a fellowship in cornea/anterior segment/refractive surgery and still remains as an active Clinical Associate Professor. Dr. Parekh also completed an MBA at the Fuqua School of Business at Duke University.   About Nordic Group B.V.
Nordic Group B.V. is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Eye Care, Rheumatology and Women’s Health. Nordic Pharma has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide.

Nordic Pharma is a part of SEVER Life Sciences, a holding company created in 2019 that
brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.
 
About Amring Pharmaceuticals Inc.
Amring Pharmaceuticals Inc., subsidiary of Nordic Group B.V., is partnered with well- established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
 
About Visant Medical, Inc.
Visant Medical is a clinical-stage medical device company. It received FDA 510(k) clearance in 2022 for LACRIFILL® cross-linked hyaluronic acid-based canalicular occlusive device. LACRIFILL is intended to block tear drainage by occlusion of the canalicular system. It is indicated for use, for up to 6 months, in patients experiencing dry eye symptoms.
Symatese SAS, a French company based in Lyon, was instrumental in the development of LACRIFILL, significantly enhancing the product's design and performance, by leveraging its expertise in tissue regeneration, reconstruction and related delivery systems. SYMATESE specializes in injectable crosslinked HA gels for many markets including Aesthetic, Rheumatology, Ophthalmology. With more than 40 researchers, SYMATESE designs the most advanced medical device solutions thanks to their technology portfolio in hyaluronic acid, collagen, thermoplastics and silicone.
 
Safe Harbor
This press release contains forward-looking statements, including, without limitation, statements related to Amring/Nordic Pharma’s business developments and the implementation of Amring/Nordic Pharma’s strategic initiatives. Because these statements reflect Amring/Nordic Pharma’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring/Nordic Pharma’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring/Nordic Pharma, and other factors that could affect Amring/Nordic Pharma’s business and financial performance. Amring/Nordic Pharma does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information,
future developments or otherwise.
 
Contact
Amring Pharmaceuticals Inc.
Kate Popova

Contracts Administration Lead

Phone : 610-285-1699

ekaterina.popova@amringpharma.com
Gail Feerrar
Director Sales and Marketing
Phone: 610-285-7152
gail.feerrar@amringpharma.com
 
NORDIC PHARMA GROUP B.V. THROUGH ITS SUBSIDIARY AMRING PHARMACEUTICALS INC., COMPLETES ACQUISITION OF VISANT MEDICAL TO LAUNCH NOVEL THERAPY FOR DRY EYE DISEASE IN THE UNITED STATES
- by admin

BERWYN, PA — Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today the completion of…

Company news

BERWYN, PA -- Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today the completion of its acquisition of Visant Medical, Inc. (Visant), a leader in medical technology innovation in Dry Eye Disease (DED). This acquisition unites Nordic Pharma's pharmaceutical expertise, with Visant's FDA-cleared hyaluronic acid derivative LACRIFILL® canalicular occlusive device, which is intended to temporarily block tear drainage by the occlusion of the canalicular system. Nordic Pharma will launch and
commercialise LACRIFILL in the U.S. and has been chosen because of its focus on Ophthalmology.

This acquisition will enhance Nordic Pharma’s impact on the global ophthalmology market starting with the U.S. launch of LACRIFILL, the patented therapy for DED. “Visant is thrilled to be joining the Nordic Pharma group,” said Vartan Ghazarossian, Ph.D., Visant co-founder and CEO. “Our team has been passionate about bringing a truly innovative solution to patients suffering from DED and we are excited to be joining the Nordic Pharma team as we begin our commercialization efforts.”

This is the second branded medical device Nordic Pharma will introduce in the U.S. and is a complementary fit to the lead brand. Following the anticipated 2024 U.S. launch of LACRIFILL, Nordic Pharma intends to seek regulatory approval to make the product available globally.

“We’re ecstatic Visant Medical selected Nordic Pharma as their partner and for the opportunity to introduce LACRIFILL to the ophthalmologists and optometrists treating the over 16 million people diagnosed with DED in the U.S.,” said Philip Gioia, President of the U.S. team that will launch LACRIFILL under the Nordic Pharma brand. “LACRIFILL representsan innovative and elegant form factor to occlude that should become the gold standard for preoperative patient care for those with DED.”

LACRIFILL is indicated for dry eye conditions and provides relief for the symptoms of dry eye. It has received FDA 510(k) clearance and has an established CPT reimbursement code. These benefits make LACRIFILL appealing to both patients and providers.

Richard Lindstrom, MD, Founder and Attending Surgeon Emeritus at Minnesota Eye Consultants said, LACRIFILL is set to play a useful role in treating patients with the signs and
symptoms of dry eye, especially prior to refractive corneal or cataract surgery. LACRIFILL will provide the Eye Care Professional with a new and attractive option to treat patients with Dry Eye Disease within their practice.

Paul Karpecki, OD, Associate Professor, University of Pikeville, Kentucky College of Optometry; Kentucky Eye Institute; emphasized the benefits of using LACRIFILL, stating: "A  gel, consisting of cross-linked hyaluronic acid represents a significant impact in ocular health in tear conservation. The properties of the hyaluronic acid in a canalicular filler offer unique comfort and effectiveness in managing dry eye symptoms.”

Raymond James & Associates, Inc. served as exclusive financial advisor to Visant Medical, Inc. and Wilson Sonsini Goodrich & Rosati, Professional Corporation served as legal advisor. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. served as legal advisor to Amring Pharmaceuticals Inc.

About Nordic Group B.V.
Nordic Pharma is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Ophthalmology, Rheumatology and Women’s Health. Nordic Pharma has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide.Nordic Pharma is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.

About Amring Pharmaceuticals Inc.
Amring Pharmaceuticals Inc., subsidiary of Nordic Group B.V., is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market. Amring is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.

About Visant Medical, Inc.
Based in Menlo Park, CA, Visant Medical is a clinical-stage medical device company. It received FDA 510(k) clearance in 2022 for LACRIFILL® cross-linked hyaluronic acid-based canalicular occlusive device. LACRIFILL is intended to block tear drainage by occlusion of the canalicular system. It is indicated for use, for up to 6 months, in patients experiencing dry eye symptoms.
Symatese SAS, a French company based in Lyon, was instrumental in the development of LACRIFILL, significantly enhancing the product's design and performance, by leveraging its expertise in tissue regeneration, reconstruction and related delivery systems. SYMATESE specializes in injectable crosslinked HA gels for many markets including Aesthetic, Rheumatology, Ophthalmology. With more than 40 researchers, SYMATESE designs the most advanced medical device solutions thanks to their technology portfolio in hyaluronic acid, collagen, thermoplastics and silicone.

Safe Harbor
This press release contains forward-looking statements, including, without limitation, statements related to Amring/Nordic Pharma’s business developments and the implementation of Amring/Nordic Pharma’s strategic initiatives. Because these statements reflect Amring/Nordic Pharma’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring/Nordic Pharma’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring/Nordic Pharma, and other factors that could affect Amring/Nordic Pharma’s business and financial performance. Amring/Nordic Pharma does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information,
future developments or otherwise.

Contact
Amring Pharmaceuticals Inc.
Kate Popova
Contracts Administration Lead
Phone Number: 610-285-1699
ekaterina.popova@amringpharma.com

Nordic Pharma joins the Pharmaceutical Supply Chain Initiative
- by admin

We are pleased to announce that Nordic Pharma has joined the Pharmaceutical Supply Chain Initiative (PSCI) as an associate member…

Company news
We are pleased to announce that Nordic Pharma has joined the Pharmaceutical Supply Chain Initiative (PSCI) as an associate member as of February 2023. Driving sustainable change in our supply chain is a key pillar of our Corporate Social Responsibility (CSR) strategy, and this marks an important step into this direction. By joining PSCI, we will join industry experts in collectively working towards better business conditions, ultimately driving our common goal of greener supply chains. We commit to uphold the responsible business principles and continue to grow ethically, always with a long-term vision.   Small steps, big impact. Our Sustainability journey continues ! If you’d like to find out more about the PSCI, click here.
Draupnir Holdings Ltd have officially merged with Nordic Group B.V
- by admin

We are pleased to announce that as of January 2023, Draupnir Holdings Ltd which incorporates Altacor, ParaPharm Development & Transdermal…

Company news
We are pleased to announce that as of January 2023, Draupnir Holdings Ltd which incorporates Altacor, ParaPharm Development & Transdermal have officially merged with Nordic Group B.V. The new merged company will operate under the name Nordic Pharma. With this merger comes exciting opportunities to strengthen the business: combined talents and competencies, territorial expansion and product portfolio development. The new Global Company will seek long term sustainable and profitable growth in our consolidated four main therapeutic areas: Rheumatology, Women’s Health, Ophthalmology and Critical Care.   Please rest assured that our teams have been and will continue to be in contact with their counterparts in the same way they have been in the past and that we commit to continue providing the highest quality products and services. We look forward to further delivering value to our shareholders whilst working together on our common purpose of making a sustainable impact on people’s health.
nordic-pharma-home-our-organization

Our organization

Today, Nordic Pharma is:

  • 300
    Employees
    worldwide
  • 20
    Different
    countries
  • 03
    Continents – and
    counting

We are a medium-size pharmaceutical company with an entrepreneurial spirit. As such, we promote change and encourage the development of new ideas. We create opportunities for personal and professional development.

Portfolio of therapeutic areas

Nordic Pharma aims at developing products that address specific unmet medical needs of healthcare professionals and patients. Today, we have a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: Women’s Health, Rheumatology, Ophthalmology, Critical Care, Others.

Our Presence

Nordic Pharma has affiliates in most European countries and has established a global footprint with key strategic partnerships to promote and distribute our products worldwide.

Our headquarters (2)
Our affiliates (12)
Our commercial partners

Nordic Pharma

Nordic Group BV
216 Boulevard Saint Germain
75007 Paris
France
Tel: +33 (0)1 70 37 28 02

Nordic Pharma

Nordic Group BV
Siriusdreef 41
2132 WT Hoofddorp
The Netherlands
Tel: +31 (0)85 48 35 871

Nordic Pharma Netherlands

Nordic Pharma B.V.
Siriusdreef 41
2132 WT Hoofddorp
The Netherlands
Tel: +31 (0)85 48 35 871
www.nordicpharma.nl

Nordic Pharma France

Nordic Pharma SAS
251 Boulevard Pereire
75017 Paris
France
Tel: +33 (0) 1 70 37 28 00
www.nordicpharma.fr

Nordic Pharma Americas, Asia, Pacific

Nordic Pharma Inc.
www.nordicpharma.ca

Nordic Pharma Central Eastern Europe

7, Mircea Eliade Blvd
Bucharest
Romania
Tel: +40 31 620 1204

Nordic Pharma Italy

Nordic Pharma S.r.l
Strada Anulare Torre 10
20090 San Felice – Segrate (MI)
Italy
Tel: +39 02 7532629
www.nordicpharma.it

Nordic Pharma Spain

Nordic Pharma SAU
Adolfo Pérez Esquivel, 3. 2°.
Of. 17. Edificio Las Américas
III. 28232 Parque Empresarial
Las Rozas, Madrid, Spain
Tel: +34 916 404 041
www.nordicpharma.es

Nordic Pharma Switzerland

Nordic Pharma GmBH
Binzmühlestrasse 80, 8050
Zürich
Switzerland
Tel: +41 43 444 92 91
www.nordicpharma.com/nordicpharma-ch

Nordic Pharma Ireland

Nordic Pharma Ltd
Allphar Services Ltd, 4045
Kingswood Road, Citywest
Business Park, Co. Dublin
Ireland

Nordic Pharma UK

Nordic Pharma Ltd
Building 1410 Arlington Business Park
Theale,
Reading, RG7 4SA
United Kingdom
Tel: +44 (0)118 221 0150
www.nordicpharma.co.uk

Nordic Pharma Germany + Austria

Nordic Pharma GmBH
Fraunhoferstraße 4 D-85737
Ismaning
Germany
Tel: +49 (0) 89 88 96 90 68 -0
www.nordicpharma.de

Nordic Pharma Scandinavia

Nordic Drugs AB
Box 300 35, 200 61
Limhamn
Sweden
Tel: +46 40 36 66 00
www.nordicdrugs.se

Nordic Pharma Belgium + Luxembourg

Nordic Pharma N.V.
Garden Square, Laarstraat 16
2610 Wilrijk
Belgium
Tel: +32 (0)3 820 52 24
https://www.nordicpharma.be/

Click on the location for more details.
map-head-default-v5
map-france3
the-Netherlands-map-v5
map
the-Netherlands
France-map
Nordic-Canada
Romania-map-v6
Italy-map
Spain-portugal-map-v2
Switzerland-map
Nordic_Pharma_Ireland-V3-1
Nordic_Pharma_UK-V3-1
map-germany
Nordic_Drugs-v5